BR112015025408A2 - combinações de droga para tratar câncer - Google Patents

combinações de droga para tratar câncer

Info

Publication number
BR112015025408A2
BR112015025408A2 BR112015025408A BR112015025408A BR112015025408A2 BR 112015025408 A2 BR112015025408 A2 BR 112015025408A2 BR 112015025408 A BR112015025408 A BR 112015025408A BR 112015025408 A BR112015025408 A BR 112015025408A BR 112015025408 A2 BR112015025408 A2 BR 112015025408A2
Authority
BR
Brazil
Prior art keywords
cancer drug
drug combinations
combinations
cancer
drug
Prior art date
Application number
BR112015025408A
Other languages
English (en)
Other versions
BR112015025408A8 (pt
Inventor
Philip W Kantoff
Christopher J Sweeney
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of BR112015025408A2 publication Critical patent/BR112015025408A2/pt
Publication of BR112015025408A8 publication Critical patent/BR112015025408A8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
BR112015025408A 2013-04-04 2014-04-04 combinações de drogas para tratar câncer BR112015025408A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361808516P 2013-04-04 2013-04-04
PCT/US2014/033008 WO2014165779A1 (en) 2013-04-04 2014-04-04 Drug combinations to treat cancer

Publications (2)

Publication Number Publication Date
BR112015025408A2 true BR112015025408A2 (pt) 2017-07-18
BR112015025408A8 BR112015025408A8 (pt) 2018-07-10

Family

ID=50732309

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015025408A BR112015025408A8 (pt) 2013-04-04 2014-04-04 combinações de drogas para tratar câncer

Country Status (11)

Country Link
US (1) US20160082019A1 (pt)
EP (1) EP2983639A1 (pt)
JP (1) JP2016515628A (pt)
KR (1) KR20150138268A (pt)
CN (1) CN108472242A (pt)
AU (1) AU2014248001A1 (pt)
BR (1) BR112015025408A8 (pt)
CA (1) CA2908815A1 (pt)
HK (1) HK1221424A1 (pt)
MX (1) MX2015014046A (pt)
WO (1) WO2014165779A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102187034B1 (ko) 2009-01-16 2020-12-04 엑셀리시스, 인코포레이티드 암 치료용 n-(4-{〔6,7-비스(메틸옥시)퀴놀린-4-일〕옥시}페닐)-n'-(4-플루오로페닐)사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US20140057943A1 (en) 2010-09-27 2014-02-27 Exelixix, Inc. Method of Treating Cancer
BR112013020362A2 (pt) 2011-02-10 2018-05-29 Exelixis Inc processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem
US9861624B2 (en) 2012-05-02 2018-01-09 Exelixis, Inc. Method of treating cancer
KR102276348B1 (ko) 2013-03-15 2021-07-12 엑셀리시스, 인코포레이티드 N­(4­〔[6,7­비스(메틸옥시)퀴놀린­4­일]옥시〕페닐)­n′­(4­플루오로페닐)시클로프로판­1,1­디카복사미드의 대사물
ES2927651T3 (es) 2013-04-04 2022-11-10 Exelixis Inc Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
EP3105204A1 (en) 2014-02-14 2016-12-21 Exelixis, Inc. Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
CN106255499A (zh) 2014-03-17 2016-12-21 埃克塞里艾克西斯公司 卡博替尼制剂的给药
CN106715397B (zh) 2014-07-31 2021-07-23 埃克塞里艾克西斯公司 制备氟-18标记的卡博替尼及其类似物的方法
WO2016022697A1 (en) 2014-08-05 2016-02-11 Exelixis, Inc. Drug combinations to treat multiple myeloma
EP3442531A1 (en) 2016-04-15 2019-02-20 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
UA126970C2 (uk) * 2017-01-20 2023-03-01 Екселіксіс, Інк. Комбінації кабозантинібу і атезолізумабу для лікування раку
US20200345692A1 (en) * 2018-01-19 2020-11-05 Indiana University Research And Technology Corporation Therapeutic targeting of receptor tyrosine kinase inhibitor-induced androgen receptor phosphoryation in cancer
WO2019148044A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
CN116808044A (zh) 2018-06-15 2023-09-29 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
AU2019342447A1 (en) * 2018-09-18 2021-04-08 Taiho Pharmaceutical Co., Ltd. Combination therapy of acylthiourea compound and abiraterone

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE517091T1 (de) * 2003-09-26 2011-08-15 Exelixis Inc C-met-modulatoren und verwendungsverfahren
EP1773826A4 (en) * 2004-07-02 2009-06-03 Exelixis Inc MODULATORS OF C-MET AND THEIR METHOD OF USE
PL2478907T3 (pl) * 2006-08-25 2021-10-25 Janssen Oncology, Inc. Kompozycje do leczenia nowotworu
WO2008083319A1 (en) 2006-12-29 2008-07-10 Il Yang Pharmaceutical Company, Ltd. Solid state forms of enantiopure ilaprazole
KR102187034B1 (ko) * 2009-01-16 2020-12-04 엑셀리시스, 인코포레이티드 암 치료용 n-(4-{〔6,7-비스(메틸옥시)퀴놀린-4-일〕옥시}페닐)-n'-(4-플루오로페닐)사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
EA201200144A1 (ru) * 2009-07-17 2012-08-30 Экселиксис, Инк. Кристаллические формы n-[3-фтор-4-({6-(метилокси)-7-[(3-морфолин-4-илпропил)окси]хинолин-4-ил}окси)фенил]-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида
UA108618C2 (uk) * 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US20140057943A1 (en) * 2010-09-27 2014-02-27 Exelixix, Inc. Method of Treating Cancer
CN103664778B (zh) * 2013-11-27 2017-04-05 苏州摩尔医药有限公司 一种抗肿瘤治疗药物卡博替尼的合成方法

Also Published As

Publication number Publication date
CA2908815A1 (en) 2014-10-09
WO2014165779A1 (en) 2014-10-09
HK1221424A1 (zh) 2017-06-02
KR20150138268A (ko) 2015-12-09
AU2014248001A1 (en) 2015-11-19
US20160082019A1 (en) 2016-03-24
CN108472242A (zh) 2018-08-31
EP2983639A1 (en) 2016-02-17
BR112015025408A8 (pt) 2018-07-10
MX2015014046A (es) 2016-05-16
JP2016515628A (ja) 2016-05-30

Similar Documents

Publication Publication Date Title
ZA201905426B (en) Drug combinations
BR112015025408A8 (pt) combinações de drogas para tratar câncer
DK3030262T3 (da) Kombineret farmaceutisk sammensætning
BR112016009485A2 (pt) Inalador de medicamento
DK2970389T3 (da) Farmaceutiske forbindelser
BR112015026025A2 (pt) dispositivo para administração de medicamento
DK3060460T3 (da) Saddel
DK3027598T3 (da) Oxoquinazolinyl-butanamidderivater
DK2956698T5 (da) Bindestrimler
DK3052081T3 (da) Pastil
DK2946640T3 (da) Langmuir-probe
DE102013106534B8 (de) Chromatographiepipettenspitze
DK3071227T3 (da) Fiskevaccine
DK3003401T3 (da) Farmaceutisk præparat
DE112014001252A5 (de) Aufbissschiene
DK2983747T3 (da) Lægemiddelindgivelsesindretning
DK2981168T3 (da) Laminitiskile
BR112016010589A2 (pt) Plastificantes para polímeros
FI20165160A (fi) Suhteellisen paikan näyttäminen
DE112014005422A5 (de) Friktionsfalschdrallaggregat
ES1079227Y (es) Dispositivo para electroterapia
BR112016000501A2 (pt) Nalador
UA28338S (uk) Медичний пристрій-шприц
UA28339S (uk) Медичний пристрій-шприц
ES1098014Y (es) Disposicion para trabazon

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 5A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2508 DE 29-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.